Celladon Corporation receives USPTO notice of allowance covering MYDICAR for advanced center failure Celladon Corp. The patent will become issued to The Regents of the University of California and licensed solely to Celladon. Related StoriesApoE4-carrying males with Alzheimer's disease at risk of brain bleedsUtah chemists devise new way to detect DNA damageCHOP experts delay symptoms, expand lifespan in animal style of Batten diseaseWhen issued, the patent covers the usage of all adeno-associated viral vectors and routes of administration, including intracoronary, for delivery of the SERCA2a gene for the treating heart failure click here .
To determine if stress-associated biomarkers in this response could offer insight into the odds of subsequent tumor development in DCIS, the experts examined several biomarkers in biopsies of DCIS tissue both in isolation and in conjunction to determine their effects. They found that the presence of high levels of two biomarkers, cOX-2 and p16, played a critical part in the biological response to cellular stress. In particular, they discovered that tumors with high p16 and/or high COX-2 in the lack of cell proliferation reflected right stress activation and a defensive response to cellular tension.